WEBULL
WebtradeDownload

Meiji Holdings (TSE:2269) Stock Price Masks A Recovery Still Priced Richly

Simply Wall St · 2d ago

Meiji Holdings stock closed at ¥4,002 today after a steady few months, yet the new quarterly numbers tell a more complicated story than the calm price suggests. Q1 2027 basic earnings per share of ¥56.33 and net income of ¥15.27b sit against a still elevated P/E of 27x and a discounted level versus analyst fair value estimates. The market appears to be treating this as business as usual. The earnings print instead raises a sharper question about how much investors are paying for a recovery that is still being rebuilt after recent one off hits.

Like Meiji Holdings' stable share price but hesitant about paying 27x earnings while the recovery remains in progress after recent one-off impacts? Consider exploring 56 resilient stocks with low risk scores for stocks where valuations more closely reflect resilient fundamentals.

Q1 2027 Earnings Summary

  • Revenue, Q1 2027 vs Q1 2026: ¥289,401m vs ¥273,569m (up about 5.8%)
  • Net Income, Q1 2027 vs Q1 2026: ¥15,271m vs ¥10,095m (up about 51.3%)
  • Basic EPS, Q1 2027 vs Q1 2026: ¥56.33 vs ¥37.27 (up about 51.1%)
  • Trailing 12 Month Basic EPS, Q1 2027 vs Q1 2026: ¥148.49 vs ¥173.05 (down about 14.2%)

Prefer clear visuals instead of another wall of earnings tables and footnotes? See Meiji Holdings' full financial picture, including a concise valuation snapshot, in the interactive company report for Meiji Holdings.

TSE:2269 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
TSE:2269 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

Meiji Holdings Bull Story Hinges On Execution Milestones

Bulls argue Meiji Holdings is turning into a higher quality, higher margin food and pharma group as restructuring, portfolio pruning and new drugs start to bite. The latest numbers offer some support. FY25 operating profit of ¥93.3b came in above plan even though Food missed its target. That points to early cost and pricing gains plus tighter discipline, which are core to the reform story.

The case for pharmaceuticals as a profit engine also passed an early test. Pharma operating profit of ¥30.4b rose much faster than group profit and exceeded plan by ¥4.4b, helped by royalty income, REZUROCK and vaccines. FY26 guidance then calls for both Food and Pharma operating profit to be higher again, with Food targeted at ¥74b and Pharma at ¥33b. That aligns with the idea that new products and restructuring are starting to support the earnings repair bulls are looking for.

Access the analyst playbook on where the consensus could break for Meiji Holdings, because the surface looks calm but the multi year models can point to very different earnings paths. Reveal what the street is quietly projecting for the next few fiscal years with the analyst estimates for Meiji Holdings.

Meiji Holdings Bears Still See Execution Gaps

The bearish story around Meiji Holdings centers on cost inflation, weak Food volumes after price hikes, and slow execution on restructuring. The latest results give those concerns fresh support. Food operating profit missed plan by ¥2.2b despite price increases of ¥48.5b, while raw materials added ¥23b of pressure and higher promotions and logistics further squeezed margins. That fits the view that cost pressure and elasticity are eroding the benefit of price moves.

Bears also worry that new businesses and overseas Food operations will soak up cash without quick payoff. Management now describes FY26 as a recovery and reshaping year and already notes that the midterm ¥116.5b operating profit target looks difficult. The exit from most China dairy operations indicates that parts of the international portfolio have underperformed. Pharma outperformance and the FY26 ¥100b operating profit goal provide some offset, but they do not yet close the execution gap that skeptics emphasize.

After a year that included one off items and a dividend that free cash flow does not fully cover, it is fair to ask whether these are isolated issues or signs of strain beneath the headline recovery. Review the independent risk analysis for Meiji Holdings which shows 2 important warning signs

Stay Ahead With Simply Wall St

If the mix of recovery progress and execution questions around Meiji Holdings has your attention, register for free with Simply Wall St and add it to your Watchlist to track share price against fair value and watch how the thesis evolves. When you decide to build or adjust a position, use the Portfolio Command Center to cut through noise and focus on the key fundamental and valuation updates that matter. For a broader view on sentiment and scenarios, tap into the Community and see how other investors are thinking about companies like Meiji Holdings over time. By surfacing potential catalysts and risks earlier, Simply Wall St helps you move faster and stay ahead of the market.

Seeking Alternatives Beyond Meiji Holdings?

Fresh ideas often move first. The most interesting stories can be flying under the radar for now, and the ideal entry window does not stay open. Get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.